Jared H. Rowe
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jared H. Rowe has a total of 74 co-authors. Here are the top co-authors by number of shared publications:
- Arlene H. Sharpe
Department of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA
23 shared publications - Gordon J. Freeman
Department of Medical Oncology, Dana-Farber Cancer Institute
22 shared publications - Marcia C. Haigis
Department of Cell Biology, Blavatnik Institute, Harvard Medical School, Boston, USA
22 shared publications - Megan E. Fung
Department of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA
22 shared publications - Joon Seok Park
Department of Immunology, Blavatnik Institute, Harvard Medical School, Boston, Massachusetts
21 shared publications - Shakchhi Joshi
Department of Cell Biology, Blavatnik Institute, Harvard Medical School, Boston, USA
21 shared publications
Latest Publications
- Open Access
Discovery of Tcf7 regulators with clonally-resolved CRISPR screens identifies Trim28 as a mediator of CD8 T cell differentiation in tumors
Stem-like TCF7+ CD8 T cells sustain anti-tumor responses and support immune checkpoint blockade. We systematically identified regulators of this cell state using genome-wide CRISPR screens in primary T cells in vitro . Using random barcodes to link clonal relationships with guide identity and transcriptional states in single cells, we inferred differentiation trajectories and differentiation rates of CD8 T cells in tumors, while mitigating confounding clonal bias. We found that Trim28-deficient T cells in tumors were enriched in the TCF7+ cell state, depleted in cycling and terminal effector states, and uniquely generated a tissue-resident memory (TRM)-like state with increased chromatin accessibility at known TRM loci as well as repeat elements. Despite the increase in TCF7+ CD8 T cells, loss of Trim28 did not improve tumor control, likely because of reduced effector differentiation, highlighting the need for tuning the balance and dynamics of stem-like versus effector states for effective tumor clearance.
Open AccessDiscovery of Tcf7 regulators with clonally-resolved CRISPR screens identifies Trim28 as a mediator of CD8 T cell differentiation in tumors
Stem-like TCF7+ CD8 T cells sustain anti-tumor responses and support immune checkpoint blockade. We systematically identified regulators of this cell state using genome-wide CRISPR screens in primary T cells in vitro . Using random barcodes to link clonal relationships with guide identity and transcriptional states in single cells, we inferred differentiation trajectories and differentiation rates of CD8 T cells in tumors, while mitigating confounding clonal bias. We found that Trim28-deficient T cells in tumors were enriched in the TCF7+ cell state, depleted in cycling and terminal effector states, and uniquely generated a tissue-resident memory (TRM)-like state with increased chromatin accessibility at known TRM loci as well as repeat elements. Despite the increase in TCF7+ CD8 T cells, loss of Trim28 did not improve tumor control, likely because of reduced effector differentiation, highlighting the need for tuning the balance and dynamics of stem-like versus effector states for effective tumor clearance.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Age-Associated Contraction of Tumor-Specific T Cells Impairs Antitumor Immunity
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Age-Associated Contraction of Tumor-Specific T Cells Impairs Antitumor Immunity
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from Age-Associated Contraction of Tumor-Specific T Cells Impairs Antitumor Immunity
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Age-Associated Contraction of Tumor-Specific T Cells Impairs Antitumor Immunity
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from Age-Associated Contraction of Tumor-Specific T Cells Impairs Antitumor Immunity
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Age-Associated Contraction of Tumor-Specific T Cells Impairs Antitumor Immunity
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from Age-Associated Contraction of Tumor-Specific T Cells Impairs Antitumor Immunity
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Age-Associated Contraction of Tumor-Specific T Cells Impairs Antitumor Immunity
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Age-Associated Contraction of Tumor-Specific T Cells Impairs Antitumor Immunity
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Age-Associated Contraction of Tumor-Specific T Cells Impairs Antitumor Immunity
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S7 from Age-Associated Contraction of Tumor-Specific T Cells Impairs Antitumor Immunity
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Age-Associated Contraction of Tumor-Specific T Cells Impairs Antitumor Immunity
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S8 from Age-Associated Contraction of Tumor-Specific T Cells Impairs Antitumor Immunity
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from Age-Associated Contraction of Tumor-Specific T Cells Impairs Antitumor Immunity
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Age-Associated Contraction of Tumor-Specific T Cells Impairs Antitumor Immunity
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Age-Associated Contraction of Tumor-Specific T Cells Impairs Antitumor Immunity
- 24 July 2025
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 222 (10)
PD-1 regulates tumor-infiltrating CD8+ T cells in both a cell-intrinsic and a cell-extrinsic fashion
Although PD-1 inhibitors are FDA-approved for over 25 different cancers, the mechanisms contributing to response remain incompletely understood. To investigate how PD-1–deleted CD8+ T cells influence PD-1–expressing CD8+ T cells in the same tumor microenvironment, we developed an inducible PD-1 knockout (KO) model in which PD-1 is deleted on ∼50% of cells. PD-1 deletion beginning at day 7 after implantation of MC38 tumor cells led to robust tumor control. Remarkably, PD-1–expressing CD8+ T cells in the tumor had increased functionality similar to PD-1 KO CD8+ T cells. Using single-cell RNA-seq and TCR-seq, we found that the major transcriptional changes following PD-1 deletion were shared by PD-1 KO and PD-1–expressing CD8+ T cells, although PD-1 KO clones preferentially expanded. These data suggest PD-1 inhibitors not only exert cell-intrinsic effects but also may promote increased T cell function through non–cell-autonomous mechanisms, which has important implications for design of PD-1–based cancer immunotherapies.
- 24 July 2025
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 222 (10)
PD-1 regulates tumor-infiltrating CD8+ T cells in both a cell-intrinsic and a cell-extrinsic fashion
Although PD-1 inhibitors are FDA-approved for over 25 different cancers, the mechanisms contributing to response remain incompletely understood. To investigate how PD-1–deleted CD8+ T cells influence PD-1–expressing CD8+ T cells in the same tumor microenvironment, we developed an inducible PD-1 knockout (KO) model in which PD-1 is deleted on ∼50% of cells. PD-1 deletion beginning at day 7 after implantation of MC38 tumor cells led to robust tumor control. Remarkably, PD-1–expressing CD8+ T cells in the tumor had increased functionality similar to PD-1 KO CD8+ T cells. Using single-cell RNA-seq and TCR-seq, we found that the major transcriptional changes following PD-1 deletion were shared by PD-1 KO and PD-1–expressing CD8+ T cells, although PD-1 KO clones preferentially expanded. These data suggest PD-1 inhibitors not only exert cell-intrinsic effects but also may promote increased T cell function through non–cell-autonomous mechanisms, which has important implications for design of PD-1–based cancer immunotherapies.